New tacrine-derived AChE/BuChE inhibitors : Synthesis and biological evaluation of 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates
Copyright © 2017 Elsevier Masson SAS. All rights reserved..
A series of poly-functionalized tacrine-derived compounds namely 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates were designed and synthesized as cholinesterases inhibitors. The in vitro inhibition assay against AChE and BuChE demonstrated that most of compounds had potent AChE inhibitory with reserving potential of BuChE inhibition. Among them, compound 6i bearing a 4-(3-bromophenyl) moiety showed the most potent activity against AChE/BuChE (IC50s values of 0.069 and 1.35 μM, respectively). The anti-AChE activity of 6i was five times more than that of tacrine. The SAR study revealed that chloro/bromo substituent at ortho or meta position of the 4-phenyl ring can improve the anticholinesterase activity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 128(2017) vom: 10. März, Seite 237-246 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eghtedari, Mohammad [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.04.2017 Date Revised 10.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2017.01.042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM268884315 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM268884315 | ||
| 003 | DE-627 | ||
| 005 | 20231224223457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2017.01.042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0896.xml |
| 035 | |a (DE-627)NLM268884315 | ||
| 035 | |a (NLM)28189905 | ||
| 035 | |a (PII)S0223-5234(17)30060-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eghtedari, Mohammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New tacrine-derived AChE/BuChE inhibitors |b Synthesis and biological evaluation of 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.04.2017 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a A series of poly-functionalized tacrine-derived compounds namely 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates were designed and synthesized as cholinesterases inhibitors. The in vitro inhibition assay against AChE and BuChE demonstrated that most of compounds had potent AChE inhibitory with reserving potential of BuChE inhibition. Among them, compound 6i bearing a 4-(3-bromophenyl) moiety showed the most potent activity against AChE/BuChE (IC50s values of 0.069 and 1.35 μM, respectively). The anti-AChE activity of 6i was five times more than that of tacrine. The SAR study revealed that chloro/bromo substituent at ortho or meta position of the 4-phenyl ring can improve the anticholinesterase activity | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acetylcholinesterase | |
| 650 | 4 | |a Alzheimer's disease | |
| 650 | 4 | |a Butyrylcholinesterase | |
| 650 | 4 | |a Tacrine | |
| 650 | 7 | |a Cholinesterase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrans |2 NLM | |
| 650 | 7 | |a Quinolines |2 NLM | |
| 650 | 7 | |a ethyl 5-amino-4-(3-bromophenyl)-2-phenyl-6,7,8,9-tetrahydro-4H-pyrano(2,3-b)quinoline-3-carboxylate |2 NLM | |
| 650 | 7 | |a Tacrine |2 NLM | |
| 650 | 7 | |a 4VX7YNB537 |2 NLM | |
| 650 | 7 | |a Acetylcholinesterase |2 NLM | |
| 650 | 7 | |a EC 3.1.1.7 |2 NLM | |
| 650 | 7 | |a Butyrylcholinesterase |2 NLM | |
| 650 | 7 | |a EC 3.1.1.8 |2 NLM | |
| 700 | 1 | |a Sarrafi, Yaghoub |e verfasserin |4 aut | |
| 700 | 1 | |a Nadri, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdavi, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Moradi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Homayouni Moghadam, Farshad |e verfasserin |4 aut | |
| 700 | 1 | |a Emami, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Firoozpour, Loghman |e verfasserin |4 aut | |
| 700 | 1 | |a Asadipour, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Sabzevari, Omid |e verfasserin |4 aut | |
| 700 | 1 | |a Foroumadi, Alireza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 128(2017) vom: 10. März, Seite 237-246 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2017 |g day:10 |g month:03 |g pages:237-246 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2017.01.042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2017 |b 10 |c 03 |h 237-246 | ||